Nonproliferative Diabetic Retinopathy

Retina: Fourth Edition

Volumn 2-3, Issue , 2005, Pages 1271-1284

  Chew, Emily Y ^a   Ferris, Frederick L ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 50249182522     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-02598-0.50073-2     Document Type: Chapter

References (104)

1. Kuwabara T, Cogan DG Retinal vascular patterns. I. Normal architecture. Arch Ophthalmol 1960, 64:904-911.
2. Bloodworth JMB Fine structure of retina in human and canine diabetes mellitus. Vascular complications of diabetes mellitus 1967, Mosby, St Louis. S.J. Kimuara, W.M. Caygill (Eds.).
3. Engerman RL Pathogenesis of diabetic retinopathy. Diabetes 1989, 38:1203-1206.
4. Frank RN On the pathogenesis of diabetic retinopathy - a 1990 update. Ophthalmology 1991, 98:586-593.
5. Cogan DG, Toussaint D, Kuwabara T Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961, 66:366-378.
6. Frank RN Etiologic mechanisms in diabetic retinopathy. Retina, vol. 2. Medical retina 1989, Mosby, St Louis. S.J. Ryan, A.P. Schachat, R.P. Murphy (Eds.).
7. Wise GN Retinal neovascularization. Trans Am Ophthalmol Soc 1956, 54:729-826.
8. De Venecia G, Davis M, Engerman R Clinicopathologic correlations in diabetic retinopathy. I. Histology and fluorescein angiography of microaneurysms. Arch Ophthalmol 1976, 94:1766-1773.
9. Klein R, Meuer SM, Moss SE, et al. The relationship of retinal microaneurysm counts to the 4-year progression of diabetic retinopathy. Arch Ophthalmol 1989, 107:1780-1785.
10. Klein R, Meuer SM, Moss SE, et al. Retinal micro-aneurysm counts and 10-year progression of diabetic retinopathy. Arch Ophthalmol 1995, 113:1386-1391.
11. Kohner EM, Sleightholm M Does microaneurysm count reflect severity of early diabetic retinopathy?. Ophthalmology 1986, 93:586-589. The Kroc Collaborative Study Group.
12. Ferris FL, Patz A Macular edema: a complication of diabetic retinopathy. Surv Ophthalmol 1984, 28(suppl):452-461.
13. Patz A, Schatz H, Berkow JW, et al. Macular edema - an overlooked complication of diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol 1977, 77:34-42.
14. King RC Exudative diabetic retinopathy. Br J Ophthalmol 1963, 47:666-672.
15. Sigurdsson R, Begg I Organized macular plaques in exudative diabetic maculopathy. Br J Ophthalmol 1980, 64:392-397.
16. Chew EY, Klein ML, Ferris FL, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Arch Ophthalmol 1996, 114:1079-1084.
17. Klein BEK, Moss SE, Klein R, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudates. Ophthalmology 1991, 98:1261-1265.
18. Strom C, Sander B, Larsen N, et al. Diabetic macular edema assessed with optical coherence tomography and stereo fundus photography. Invest Ophthalmol Vis Sci 2002, 43:241-245.
19. Kaiser PK, Rieman CD, Sears JE, et al. Macular traction detachment and diabetic macular edema associated with poster hyaloidal traction. Am J Ophthalmol 2001, 131:44-49.
20. Massin P, Graham D, Erginay A, et al. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 2003, 135:169-177.
21. Early Treatment Diabetic Retinopathy Study Research Group Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report no 12. Ophthalmology 1991, 98:823-833.
22. Murphy RP Management of diabetic retinopathy. Am Fam Phys 1995, 51:785-796.
23. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. ETDRS report no 1. Arch Ophthalmol 1985, 103:1796-1806.
24. Wilkinson CP, Ferris FL, Klein RE, et al. Proposed internation clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003, 110:1677-1682.
25. Centers for Disease Control (). http://www.cdc.gov/diabetes/news/docs/dpp.htm.
26. The Eye Disease Prevalence Research Group The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004, 122:552-563.
27. Harris M, Flega KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998, 21:518-524.
28. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984, 102:520-526.
29. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984, 102:527-532.
30. Klein R, Klein BEK, Moss SE, et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?. Arch Intern Med 1989, 149:2427-2432.
31. Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
32. Diabetes Control and Complications Trial Research Group The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol 1995, 113:36-51.
33. 1C) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995, 44:968-983.
34. Diabetes Control and Complications Trial Research Group Perspectives in diabetes: the absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996, 45:1289-1298.
35. Reichard P, Nilsson BY, Rosenqvist U The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993, 329:304-309.
36. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study Research Group Effects of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287:2563-2569.
37. Klein R, Klein B, Moss S Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996, 124:90-96.
38. Ohkubo Y, Hideke K, Eiichi A, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
39. UK Prospective Diabetes Study Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1988, 352:854-865.
40. UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1988, 352:837-853.
41. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Br Med J 1998, 317:703-713.
42. Chaturvedi N, Sjolie AK, Stephen JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998, 351:28-31.
43. Fong DS, Segal PP, Myers F, et al. Subretinal fibrosis in diabetic macular edema. ETDRS report no 23. Arch Ophthalmol 1997, 115:873-877.
44. Lyons TJ, Jenkins AJ, Zhen D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalm Vis Sci 2004, 45:910-918.
45. Kostraba JN, Klein R, Dorman JS, et al. The epidemiology of diabetes complications study. IV. Correlates of diabetic background and proliferative retinopathy. Am J Epidemiol 1991, 133:381-391.
46. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care 1995, 18:631-637.
47. Klein BEK, Moss SE, Klein R Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990, 13:34-40.
48. Phelps RL, Sakol P, Metzger BE, et al. Changes in diabetic retinopathy during pregnancy: correlations with regulation of hyperglycemia. Arch Ophthalmol 1986, 104:1806-1810.
49. The Diabetes Control and Complications Trial Research Group Effect of pregnancy on the microvascular complications. Diabetes Care 2000, 23:1084-1091.
50. American Academy of Ophthalmology Preferred practice pattern. Diabetic retinopathy no. 110020 1998, AAO, San Francisco.
51. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss. ETDRS report no. 18. Invest Ophthalmol Vis Sci 1998, 39:233-252.
52. Janka HU, Warram JH, Rand LI, et al. Risk factors for progression of background retinopathy in long-standing IDDM. Diabetes 1989, 38:460-464.
53. Rand LI, Prud'homme GJ, Ederer F, et al. Factors influencing the development of visual loss in advanced diabetic retinopathy. DRS report no. 10. Invest Ophthalmol Vis Sci 1985, 26:983-991.
54. Berman DH, Friedman EA Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythropoietin. Retina 1994, 14:1-5.
55. Qiao Q, Keinanen-Kiukaanniemi S, Laara E The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol 1997, 50:153-158.
56. Shorb SR Anemia and diabetic retinopathy. Am J Ophthalmol 1985, 100:434-436.
57. Krolewski AS, Barzilay J, Warram JH, et al. Risk of early-onset proliferative diabetic retinopathy in IDDM is closely related to cardiovascular autonomic neuropathy. Diabetes 1992, 41:430-437.
58. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM complications study. Diabetologia 1996, 39:1377-1384.
59. Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy. DRS report no 2. Ophthalmology 1978, 85:82-105.
60. Diabetic Retinopathy Study Research Group Four risk factors for severe visual loss in diabetic retinopathy. DRS report no 3. Arch Ophthalmol 1979, 97:654-655.
61. Diabetic Retinopathy Study Research Group Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report no 8. Ophthalmology 1981, 88:583-600.
62. Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Dev Ophthalmol 1981, 2:248-261.
63. Early Treatment Diabetic Retinopathy Study Research Group Techniques for scatter and local photocoagulation treatment of diabetic retinopathy. ETDRS report no. 3. Int Ophthalmol Clin 1987, 27:254-264.
64. Early Treatment Diabetic Retinopathy Study Research Group Early photocoagulation for diabetic retinopathy. ETDRS report no. 9. Ophthalmology 1991, 98(suppl):767-785.
65. Ferris F Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc 1996, 94:505-537.
66. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. ETDRS report no. 4. Int Ophthalmol Clin 1987, 27:265-272.
67. Early Treatment Diabetic Retinopathy Study Research Group Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS report no. 2. Ophthalmology 1987, 94:761-774.
68. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema: relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline. ETDRS report no. 19. Arch Ophthalmol 1995, 113:1144-1155.
69. Han DP, Miller WF, Burton TC Submacular fibrosis after photocoagulation for diabetic macular edema. Am J Ophthalmol 1992, 113:513-521.
70. Lewis H, Schachat AP, Haimann MH, et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 1990, 97:503-511.
71. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002, 109:920-927.
72. Jonas JB, Kreissing I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2003, 121:57-61.
73. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema. Ophthalmology 2004, 111:218-225.
74. Brown JC, Soloman S, Bressler SB, et al. Detection of diabetic foveal edema. Contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol 2004, 122:330-335.
75. Dipyridamole Aspirin Microangiopathy of Diabetes Study Group Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter, randomized, controlled clinical trial. Diabetes 1989, 38:491-498.
76. Ticlopidine Microangiography of Diabetes Study Group Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990, 108:1577-1583.
77. Carroll WW, Geeraets WJ Diabetic retinopathy and salicylates. Ann Ophthalmol 1972, 4:1019-1046.
78. Kuwabara T, Cogan DG Retinal vascular patterns. VI. Mural cells of retinal capillaries. Arch Ophthalmol 1963, 69:492-502.
79. Powell EDU, Field RA Diabetic retinopathy and rheumatoid arthritis. Lancet 1964, 2:17-18.
80. Regnault F Role des plaguettes dans la pathogenie de la retinopathie diabetique. Sem Hop Paris 1972, 48:893-902.
81. Sagel J, Colwell JA, Crook L, et al. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 1975, 82:733-738.
82. Chew EY, Klein ML, Murphy RP, et al. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. ETDRS report no. 20. Arch Ophthalmol 1995, 113:52-55.
83. Early Treatment Diabetic Retinopathy Study Research Group Effects of aspirin treatment on diabetic retinopathy. ETDRS report no. 8. Ophthalmology 1991, 98:757-765.
84. Early Treatment Diabetic Retinopathy Study Research Group Aspirin effects on mortality and morbidity in patients with diabetes mellitus. ETDRS report no. 14. JAMA 1992, 268:1292-1300.
85. Frank RN Perspectives in diabetes: the aldose reductase controversy. Diabetes 1994, 43:169-172.
86. Engerman RL, Kern TS Experimental galactosemia produces diabetic-like retinopathy. Diabetes 1984, 33:97-100.
87. Kador PF, Akagi Y, Takahashi Y, et al. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1990, 108:1301-1309.
88. Kador PF, Akagi Y, Takahashi Y, et al. Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1988, 106:1099-1102.
89. Robison WG, Laver NM, Jacot JL, et al. Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509. Invest Ophthalmol Vis Sci 1996, 37:1149-1156.
90. Robison WG, Nagata M, Laver N, et al. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Vis Sci 1989, 30:2285-2292.
91. Sorbinil Retinopathy Trial Research Group A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990, 108:1234-1244.
92. Sorbinil Retinopathy Trial Research Group The sorbinil retinopathy trial: neuropathy results. Neurology 1993, 43:1141-1149.
93. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VGEF-receptor dimeric proteins. Proc Nat Acad Sci USA 1995, 92:10457-10461.
94. Brownlee M, Cerami A, Vlassara H Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1986, 318:1315-1321.
95. Brownlee M, Vlassara H, Kooney A, et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986, 232:1629-1632.
96. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276:1706-1709.
97. Moss S, Klein R, Klein B Factors associated with having eye examinations in persons with diabetes. Arch Fam Med 1995, 4:529-534.
98. Sprafka J, Fritsc T, Baker R, et al. Prevalence of undiagnosed eye disease in high-risk diabetic individuals. Arch Intern Med 1990, 150:857-861.
99. Will J, German R, Schuman E, et al. Patient adherence to guidelines for diabetes eye care: results from the diabetic eye disease follow-up study. Am J Public Health 1994, 84:1669-1671.
100. Klein R Eye-care delivery for people with diabetes (commentary). Diabetes Care 1994, 17:614-615.
101. Klein R Barriers to prevention of vision loss caused by diabetic retinopathy (editorial). Arch Ophthalmol 1997, 115:1073-1075.
102. Kupfer C The challenge of transferring research results into patient care. Ophthalmology 1989, 96:737-738.
103. Ackerman SJ Benefits of preventive programs in eye care are visible on the bottom line. Diabetes Care 1992, 15:580-581.
104. Diabetes Control and Complications Trial Research Group Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996, 276:1409-1415.